SCHEMBL3011490

SCHEMBL3011490

CCCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Br)ccc4OC)CC3)n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
GLA P06280 1/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.36
DRD2 P14416 6/20 0.36
DRD4 P21917 5/20 0.36
DRD3 P35462 5/20 0.36
TSHR P16473 2/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
PPARG P37231 1/20 0.35
GFER P55789 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
ERBB2 P04626 1/20 0.33
EPHA2 P29317 1/20 0.33
KDR P35968 1/20 0.33
EPHB4 P54760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010620 0.93 GAA (0.38) SMN1; SMN2GLAGAAALOX15DRD2
SCHEMBL3019945 0.92 GAA (0.39) SMN1; SMN2GLAGAAALOX15DRD2
SCHEMBL3014666 0.92 ALDH1A1 (0.41) SMN1; SMN2GAAALOX15DRD2DRD4
SCHEMBL15671681 0.91 MAPT (0.38) SMN1; SMN2GLAGAAALOX15DRD2
SCHEMBL3016470 0.91 ALDH1A1 (0.42) SMN1; SMN2TSHRALDH1A1LMNARAB9A
SCHEMBL3013312 0.91 GAA (0.39) SMN1; SMN2GLAGAAALOX15DRD2
SCHEMBL3007655 0.91 DRD2 (0.45) GAAALOX15DRD2DRD4DRD3
SCHEMBL3017874 0.90 LMNA (0.36) SMN1; SMN2GLAGAAALOX15DRD2
SCHEMBL3003698 0.90 CYP3A4 (0.39) SMN1; SMN2TSHRALDH1A1LMNAMAPT
SCHEMBL3004621 0.89 DRD2 (0.41) SMN1; SMN2GLAGAAALOX15DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885GLA 1152/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.